{"result": "(\"entity\"<|>CORTICOIDS<|>ORGANIZATION<|>Corticoids are a class of steroid hormones used in cancer treatment to help manage symptoms and improve appetite.)\n##\n(\"entity\"<|>TESTOSTERONE DERIVATIVES<|>ORGANIZATION<|>Testosterone derivatives are anabolic agents considered for therapeutic use in cancer patients to counteract muscle mass loss.)\n##\n(\"entity\"<|>ACETATE DE MEGESTROL<|>ORGANIZATION<|>Acetate de Megestrol is a medication used to stimulate appetite in cancer patients, showing effectiveness in clinical trials.)\n##\n(\"entity\"<|>MICRONUTRIENTS<|>ORGANIZATION<|>Micronutrients are essential vitamins and minerals that are often deficient in cancer patients, impacting their overall health.)\n##\n(\"entity\"<|>SUPLEMENTOS VITAMÍNICOS<|>ORGANIZATION<|>Vitamin supplements are often used by cancer patients, though high doses may not provide benefits and could be harmful.)\n##\n(\"entity\"<|>QUIMIOTERAPIA<|>EVENT<|>Chemotherapy is a common treatment for cancer that can lead to nutritional deficiencies and requires careful management of vitamin intake.)\n##\n(\"relationship\"<|>ACETATE DE MEGESTROL<|>CANCER<|>Acetate de Megestrol is used to stimulate appetite in cancer patients, making it a relevant treatment option<|>8)\n##\n(\"relationship\"<|>CORTICOIDS<|>CANCER<|>Corticoids are used in cancer treatment to help manage symptoms and improve appetite<|>7)\n##\n(\"relationship\"<|>TESTOSTERONE DERIVATIVES<|>CANCER<|>Testosterone derivatives are considered for use in cancer patients to help maintain muscle mass<|>6)\n##\n(\"relationship\"<|>MICRONUTRIENTS<|>CANCER<|>Micronutrient deficiencies are common in cancer patients, necessitating careful dietary management<|>8)\n##\n(\"relationship\"<|>SUPLEMENTOS VITAMÍNICOS<|>CANCER<|>Vitamin supplements are frequently used by cancer patients, although their efficacy and safety can vary<|>5)\n##\n(\"relationship\"<|>QUIMIOTERAPIA<|>CANCER<|>Chemotherapy is a primary treatment for cancer that can lead to nutritional challenges<|>9)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: puedan mejorar con este tratamiento. En ciclos más prolongados de tratamiento, es preferible el acetato de megestrol.\n\n- Anabolizantes: debido a que en el cáncer existe un descenso de la masa muscular, los derivados de la testosterona se han considerado como una posible opción terapéutica. Aunque han demostrado efectos positivos en algunos ensayos clínicos, son menos efectivos que el acetato de megestrol y los corticoides. Su uso tiene efectos anabólicos al incrementar la síntesis proteica, especialmente en células musculares, pero también virilizantes y afectan al comportamiento. Los moduladores selectivos del receptor de andrógenos actúan selectivamente sobre el músculo. Se encuentra en estudio en fase II el primer agente de esta clase: enobosarm, que ha demostrado incrementar la masa magra, la fuerza y la velocidad.\n\n- Dronabinol, comercializado en EEUU, es una forma sintética de terahidrocannabinoide (el componente activo de la marihuana), y también se ha empleado como estimulante del apetito y como antiemético. Los cannabinoides se unen a los receptores del sistema endocannabinoide, que regulan el apetito, el dolor y funciones de la memoria. Han demostrado propiedades psicoactivas, produciendo efectos secundarios como vértigo, psicosis y alteraciones cardiovasculares. Los efectos sobre el apetito son variables, con escasos resultados sobre el peso. Ensayos clínicos que han comparado su eficacia con el acetato de megestrol, han demostrado la superioridad de este último.\n\nOtros estimuladores del apetito: la grelina ha demostrado aumentar el apetito en sujetos sanos y con cáncer. Sin embargo, su uso clínico se ve limitado por la corta vida media y la necesidad de administración parenteral, por lo que no está actualmente comercializado. La anamorelina, un análogo de la grelina, ha demostrado que mejora el apetito, el peso corporal y la masa magra, en estudios en fase III, aunque todavía no está disponible.\n\n## 5.3. Vitaminas y oligoelementos\n\nEn todos los pacientes malnutridos hay un riesgo de deficiencia de micronutrientes, especialmente de vitaminas hidrosolubles. En relación con los requerimientos de elementos traza y vitaminas hidrosolubles en los pacientes oncológicos, la American Cancer Society ha establecido que, debido al pobre patrón alimentario que presentan muchos pacientes, el empleo de un multi-vitamínico en dosis fisiológicas es una medida segura y útil, también durante la quimio y la radioterapia. Sin embargo, muchos pacientes consumen suplementos vitamínicos en dosis muy superiores a las recomendadas. La utilización de megadosis de vitaminas, no ha demostrado efectos beneficiosos11, y la utilización de determinados suplementos a dosis altas, podría incluso resultar perjudicial. Durante la quimioterapia con metotrexato u otros antimetabolitos que actúan por un mecanismo antifolatos, existen dudas sobre la seguridad del uso de suplementos de ácido fólico, ya que podrían disminuir la eficacia de dichos tratamientos. En general, no se recomienda el uso de vitaminas en cantidades superiores a las RDA. Las principales recomendaciones de la toma de vitaminas elaboradas por el Instituto Americano del Cáncer se recogen en la tabla 423, 24.\n\nEl déficit de vitamina D es altamente prevalente en los pacientes oncológicos, debido a la menor exposición solar y a la disminución de la ingesta. Existen estudios que correlacionan el déficit de vitamina D con la incidencia y el pronóstico de determinados tipos de cáncer, aunque se necesitarían estudios prospectivos para probar estas observaciones. En cualquier caso, debido a los conocidos efectos beneficiosos de la vitamina D sobre el sistema muscular y esquelético, se recomienda determinar las niveles de vitamina D en el paciente oncológico y suplementar para alcanzar la cifra recomendada (>30 ng/dl), igual que en población general.\n\nEn general, el uso de dosis altas de micronutrientes debe evitarse. Pese a esto, se estima que aproximadamente el 50% de los pacientes oncológicos, utiliza productos o medicinas alternativas con dosis altas de vitaminas y antioxidantes. Un metanálisis con 68 estudios no halla ningún efecto beneficioso de la toma de antioxidantes, sino una mortalidad ligeramente superior en aquellos pacientes que consumían betacaroteno, vitamina A o vitamina E25.\n\n## 6. Soporte nutricional\n\nLa vía preferida para lograr una nutrición adecuada es la oral, intentando primero una modificación en la dieta tradicional. Cuando pese a estas modificaciones el paciente presente carencias nutricionales, nos plantearemos avanzar el soporte nut\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>AMERICAN CANCER SOCIETY<|>ORGANIZATION<|>The American Cancer Society is an organization that provides guidelines and recommendations for cancer patients, including nutritional advice and vitamin intake.)\n##\n(\"entity\"<|>ENOBOSARM<|>ORGANIZATION<|>Enobosarm is a selective androgen receptor modulator currently in phase II studies, showing potential to increase lean mass and strength in patients.)\n##\n(\"entity\"<|>DRONABINOL<|>ORGANIZATION<|>Dronabinol is a synthetic form of THC used in the U.S. as an appetite stimulant and antiemetic, affecting the endocannabinoid system.)\n##\n(\"entity\"<|>GRELIN<|>ORGANIZATION<|>Ghrelin is a hormone that stimulates appetite, with clinical use limited due to its short half-life and need for parenteral administration.)\n##\n(\"entity\"<|>ANAMORELIN<|>ORGANIZATION<|>Anamorelin is a ghrelin analog that has shown improvements in appetite, body weight, and lean mass in phase III studies, but is not yet available.)\n##\n(\"entity\"<|>VITAMIN D<|>ORGANIZATION<|>Vitamin D is a micronutrient that is often deficient in cancer patients, with known benefits for the muscular and skeletal systems.)\n##\n(\"entity\"<|>MULTI-VITAMIN<|>ORGANIZATION<|>Multi-vitamins are recommended by the American Cancer Society for malnourished cancer patients to address deficiencies in vitamins and trace elements.)\n##\n(\"entity\"<|>CANCER<|>EVENT<|>Cancer is a disease characterized by the uncontrolled growth of abnormal cells, often leading to various health complications and nutritional deficiencies.)\n##\n(\"relationship\"<|>AMERICAN CANCER SOCIETY<|>MULTI-VITAMIN<|>The American Cancer Society recommends the use of multi-vitamins for cancer patients to prevent deficiencies<|>8)\n##\n(\"relationship\"<|>ENOBOSARM<|>CANCER<|>Enobosarm is being studied as a treatment option for cancer patients to help increase muscle mass<|>7)\n##\n(\"relationship\"<|>DRONABINOL<|>CANCER<|>Dronabinol is used in cancer treatment to stimulate appetite and reduce nausea<|>8)\n##\n(\"relationship\"<|>GRELIN<|>CANCER<|>Ghrelin is studied for its potential to increase appetite in cancer patients<|>6)\n##\n(\"relationship\"<|>ANAMORELIN<|>CANCER<|>Anamorelin is being researched for its effects on appetite and weight in cancer patients<|>7)\n##\n(\"relationship\"<|>VITAMIN D<|>CANCER<|>Vitamin D levels are correlated with cancer incidence and prognosis, making it important for cancer patients<|>9)\n##\n(\"relationship\"<|>VITAMIN D<|>AMERICAN CANCER SOCIETY<|>The American Cancer Society recommends monitoring and supplementing Vitamin D levels in cancer patients<|>8)\n<|COMPLETE|>"}]}